Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419515 | 1.00 | SCN9A (0.36) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL2646342 | 1.00 | SCN9A (0.36) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL20492529 | 0.98 | SCN9A (0.35) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL14135102 | 0.95 | SCN9A (0.33) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL28120063 | 0.95 | SCN9A (0.33) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL248747 | 0.86 | NOS2 (0.39) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL40093 | 0.86 | NOS2 (0.39) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL248746 | 0.86 | NOS2 (0.39) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| SCHEMBL632759 | 0.85 | SCN9A (0.35) | SCN9ASCN3ASCN5ADPP4DPP8 | |
| Hydrochloric Acid SCHEMBL661790 | 0.84 | NOS2 (0.38) | SCN9ASCN3ASCN5ADPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3707140-A1 | PURINE BASED COMPOUNDS AS TOLL-LIKE RECEPTOR 9 ANTAGONIST | Council of Scientific and Industrial Research (IN) | 2020-09-16 | — | — | EP | claimed |
| WO-2023226965-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| WO-2020248123-A1 | HYDROXYPYRROLIDINE-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3707140-A1 | PURINE BASED COMPOUNDS AS TOLL-LIKE RECEPTOR 9 ANTAGONIST | Council of Scientific and Industrial Research (IN) | 2020-09-16 | — | — | EP | disclosed |
| EP-3679051-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XW Laboratories Inc. (KY) | 2020-07-15 | — | — | EP | disclosed |
| EP-3668837-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XW Laboratories Inc. (KY) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019041361-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XW LABORATORIES, INC. (CN) | 2019-03-07 | — | — | WO | disclosed |
| CN-105968101-B | Application as the compound of hepatitis c inhibitor and its in drug | 广东东阳光药业有限公司 | 2019-03-01 | — | — | CN | disclosed |
| WO-2019033330-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XW LABORATORIES, INC. (CN) | 2019-02-21 | — | — | WO | disclosed |
| EP-2121603-A2 | 6' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008101247-A2 | 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1404325-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002096420-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1127049-A1 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL Holdings, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1105112-A2 | COMPOSITIONS AND USES FOR VISION AND MEMORY DISORDERS | GPI NIL Holdings, Inc. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000016603-A2 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL HOLDINGS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0983054-A1 | HAIR GROWTH COMPOSITIONS AND USES | GPI NIL Holdings, Inc. (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-2000009108-A2 | COMPOSITIONS AND USES FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1998055090-A1 | HAIR GROWTH COMPOSITIONS AND USES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | SCN9A 3732/4885SCN3A 2288/4885SCN5A 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.